Article
Characterization of potent ABCG2 inhibitor derived from chromone: from the mechanism of inhibition to human extracellular vesicles for drug delivery
Registro en:
VALDAMERI, Glaucio et al. Characterization of potent ABCG2 inhibitor derived from chromone: from the mechanism of inhibition to human extracellular vesicles for drug delivery. Pharmaceutics, v. 15, n. 1259, p. 1-17, 2023.
1999-4923
Autor
Valdameri, Glaucio
Kita, Diogo Henrique
Dutra, Julia de Paula
Gomes, Diego Lima
Tonduru, Arun Kumar
Kronenberger, Thales
Gavinho, Bruno
Rossi, Izadora Volpato
Carvalho, Mariana Mazetto de
Pérès, Basile
Zattoni, Ingrid Fatima
Rego, Fabiane Gomes de Moraes
Picheth, Geraldo
Freitas, Rilton Alves de
Poso, Antti
Ambudkar, Suresh V.
Ramírez, Marcel Ivan
Boumendjel, Ahcène
Moure, Vivian Rotuno
Resumen
Inhibition of ABC transporters is a promising approach to overcome multidrug resistance in cancer. Herein, we report the characterization of a potent ABCG2 inhibitor, namely, chromone 4a (C4a). Molecular docking and in vitro assays using ABCG2 and P-glycoprotein (P-gp) expressing membrane vesicles of insect cells revealed that C4a interacts with both transporters, while showing selectivity toward ABCG2 using cell-based transport assays. C4a inhibited the ABCG2-mediated efflux of different substrates and molecular dynamic simulations demonstrated that C4a binds in the Ko143-binding pocket. Liposomes and extracellular vesicles (EVs) of Giardia intestinalis and human blood were used to successfully bypass the poor water solubility and delivery of C4a as assessed by inhibition of the ABCG2 function. Human blood EVs also promoted delivery of the well-known P-gp inhibitor, elacridar. Here, for the first time, we demonstrated the potential use of plasma circulating EVs for drug delivery of hydrophobic drugs targeting membrane proteins.